Rigel Long Term Debt vs Deferred Long Term Liab Analysis

RIGL Stock

USD 21.57 0.71 3.40%

Rigel Pharmaceuticals financial indicator trend analysis is much more than just breaking down Rigel Pharmaceuticals prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Rigel Pharmaceuticals is a good investment. Please check the relationship between Rigel Pharmaceuticals Long Term Debt and its Deferred Long Term Liab accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Rigel Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

For more information on how to buy Rigel Stock please use our How to buy in Rigel Stock guide.

Long Term Debt vs Deferred Long Term Liab

Long Term Debt vs Deferred Long Term Liab Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Rigel Pharmaceuticals Long Term Debt account and Deferred Long Term Liab. At this time, the significance of the direction appears to have strong contrarian relationship.

The correlation between Rigel Pharmaceuticals' Long Term Debt and Deferred Long Term Liab is -0.56. Overlapping area represents the amount of variation of Long Term Debt that can explain the historical movement of Deferred Long Term Liab in the same time period over historical financial statements of Rigel Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Rigel Pharmaceuticals' Long Term Debt and Deferred Long Term Liab is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Long Term Debt of Rigel Pharmaceuticals are associated (or correlated) with its Deferred Long Term Liab. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Deferred Long Term Liab has no effect on the direction of Long Term Debt i.e., Rigel Pharmaceuticals' Long Term Debt and Deferred Long Term Liab go up and down completely randomly.

Correlation Coefficient

-0.56

Relationship Direction	Negative
Relationship Strength	Very Weak

View All Relationships

Long Term Debt

Long-term debt is a debt that Rigel Pharmaceuticals has held for over one year. Long-term debt appears on Rigel Pharmaceuticals balance sheet and also includes long-term leases. The most common forms of long term debt are bonds payable, long-term notes payable, mortgage payable, pension liabilities, and lease liabilities. In the corporate world, long-term debt is generally used to fund big-ticket items, such as machinery, buildings, and land. The total of long-term debt reported on Rigel Pharmaceuticals balance sheet is the sum of the balances of all categories of long-term debt. Debt that is not due within the current year and is often considered to be financing activities that are to be repaid over several years.

Deferred Long Term Liab

Liabilities that are due after more than one year, including deferred tax liabilities and deferred revenue.

Most indicators from Rigel Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Rigel Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Rigel Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

For more information on how to buy Rigel Stock please use our How to buy in Rigel Stock guide.At this time, Rigel Pharmaceuticals' Selling General Administrative is quite stable compared to the past year. Tax Provision is expected to grow at the current pace this year, although the value of Sales General And Administrative To Revenue will most likely fall to 1.34.

	2022	2024	2025 (projected)
Interest Income	684K	2.3M	1.2M
Non Recurring	1.3M	1.2M	1.1M

Interest Income Non Recurring

Rigel Pharmaceuticals fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Common Stock	Other Liab	Current Deferred Revenue
Total Assets		-0.14	-0.26	-0.21	0.79	-0.02	-0.25	0.0	-0.14	0.08	-0.1	0.34	0.94	-0.1	-0.04	0.19	-0.11	0.03	0.21	-0.15	-0.02	0.99	0.14	-0.04	-0.01	-0.11
Short Long Term Debt Total	-0.14		0.85	0.83	-0.65	0.04	0.65	-0.59	0.42	0.28	0.77	0.61	-0.37	0.87	0.81	-0.39	0.9	0.49	0.42	0.9	0.16	-0.21	0.5	0.81	0.81	0.17
Other Current Liab	-0.26	0.85		0.92	-0.77	-0.11	0.65	-0.7	0.58	0.16	0.61	0.44	-0.47	0.87	0.83	-0.4	0.92	0.5	0.49	0.95	0.18	-0.31	0.41	0.83	0.9	0.19
Total Current Liabilities	-0.21	0.83	0.92		-0.73	0.22	0.67	-0.74	0.56	0.13	0.78	0.3	-0.45	0.81	0.84	-0.32	0.87	0.7	0.54	0.95	0.47	-0.28	0.51	0.84	0.8	0.49
Total Stockholder Equity	0.79	-0.65	-0.77	-0.73		-0.05	-0.66	0.4	-0.43	0.03	-0.55	-0.08	0.91	-0.64	-0.52	0.45	-0.68	-0.36	-0.13	-0.72	-0.22	0.84	-0.21	-0.52	-0.58	-0.25
Property Plant And Equipment Net	-0.02	0.04	-0.11	0.22	-0.05		0.24	-0.08	-0.17	-0.27	0.57	-0.37	-0.12	-0.12	0.09	0.13	-0.04	0.62	0.06	0.05	0.88	-0.1	0.44	0.09	-0.22	0.58
Net Debt	-0.25	0.65	0.65	0.67	-0.66	0.24		-0.27	0.29	-0.52	0.8	0.43	-0.46	0.76	0.4	-0.67	0.81	0.47	0.09	0.79	0.38	-0.33	0.37	0.4	0.73	0.19
Retained Earnings	0.0	-0.59	-0.7	-0.74	0.4	-0.08	-0.27		-0.5	-0.42	-0.45	-0.25	0.2	-0.56	-0.91	-0.09	-0.55	-0.61	-0.91	-0.64	-0.26	0.05	-0.41	-0.91	-0.5	-0.26
Accounts Payable	-0.14	0.42	0.58	0.56	-0.43	-0.17	0.29	-0.5		0.12	0.34	-0.02	-0.35	0.68	0.47	-0.23	0.49	0.28	0.43	0.53	0.11	-0.18	-0.11	0.46	0.51	0.32
Cash	0.08	0.28	0.16	0.13	0.03	-0.27	-0.52	-0.42	0.12		-0.14	0.13	0.09	0.02	0.45	0.42	-0.01	-0.01	0.45	0.04	-0.31	0.1	0.06	0.45	-0.02	0.02
Non Current Assets Total	-0.1	0.77	0.61	0.78	-0.55	0.57	0.8	-0.45	0.34	-0.14		0.31	-0.36	0.71	0.61	-0.34	0.75	0.68	0.3	0.78	0.61	-0.21	0.5	0.62	0.57	0.54
Non Currrent Assets Other	0.34	0.61	0.44	0.3	-0.08	-0.37	0.43	-0.25	-0.02	0.13	0.31		0.22	0.56	0.38	-0.35	0.62	-0.01	0.23	0.52	-0.36	0.31	0.25	0.39	0.63	-0.27
Cash And Short Term Investments	0.94	-0.37	-0.47	-0.45	0.91	-0.12	-0.46	0.2	-0.35	0.09	-0.36	0.22		-0.36	-0.25	0.32	-0.35	-0.22	0.01	-0.4	-0.19	0.97	-0.01	-0.25	-0.24	-0.23
Net Receivables	-0.1	0.87	0.87	0.81	-0.64	-0.12	0.76	-0.56	0.68	0.02	0.71	0.56	-0.36		0.72	-0.58	0.95	0.44	0.39	0.93	0.12	-0.17	0.31	0.72	0.91	0.14
Common Stock Total Equity	-0.04	0.81	0.83	0.84	-0.52	0.09	0.4	-0.91	0.47	0.45	0.61	0.38	-0.25	0.72		-0.05	0.73	0.62	0.77	0.79	0.25	-0.1	0.5	1.0	0.65	0.23
Common Stock Shares Outstanding	0.19	-0.39	-0.4	-0.32	0.45	0.13	-0.67	-0.09	-0.23	0.42	-0.34	-0.35	0.32	-0.58	-0.05		-0.6	-0.3	0.21	-0.52	-0.09	0.22	-0.38	-0.05	-0.62	0.24
Non Current Liabilities Total	-0.11	0.9	0.92	0.87	-0.68	-0.04	0.81	-0.55	0.49	-0.01	0.75	0.62	-0.35	0.95	0.73	-0.6		0.52	0.37	0.98	0.21	-0.18	0.47	0.74	0.96	0.15
Other Current Assets	0.03	0.49	0.5	0.7	-0.36	0.62	0.47	-0.61	0.28	-0.01	0.68	-0.01	-0.22	0.44	0.62	-0.3	0.52		0.55	0.6	0.82	-0.06	0.83	0.61	0.43	0.36
Other Stockholder Equity	0.21	0.42	0.49	0.54	-0.13	0.06	0.09	-0.91	0.43	0.45	0.3	0.23	0.01	0.39	0.77	0.21	0.37	0.55		0.44	0.19	0.16	0.35	0.76	0.34	0.19
Total Liab	-0.15	0.9	0.95	0.95	-0.72	0.05	0.79	-0.64	0.53	0.04	0.78	0.52	-0.4	0.93	0.79	-0.52	0.98	0.6	0.44		0.31	-0.22	0.5	0.8	0.93	0.28
Property Plant And Equipment Gross	-0.02	0.16	0.18	0.47	-0.22	0.88	0.38	-0.26	0.11	-0.31	0.61	-0.36	-0.19	0.12	0.25	-0.09	0.21	0.82	0.19	0.31		-0.1	0.58	0.25	0.11	0.58
Total Current Assets	0.99	-0.21	-0.31	-0.28	0.84	-0.1	-0.33	0.05	-0.18	0.1	-0.21	0.31	0.97	-0.17	-0.1	0.22	-0.18	-0.06	0.16	-0.22	-0.1		0.09	-0.1	-0.06	-0.17
Short Term Debt	0.14	0.5	0.41	0.51	-0.21	0.44	0.37	-0.41	-0.11	0.06	0.5	0.25	-0.01	0.31	0.5	-0.38	0.47	0.83	0.35	0.5	0.58	0.09		0.5	0.41	-0.02
Common Stock	-0.04	0.81	0.83	0.84	-0.52	0.09	0.4	-0.91	0.46	0.45	0.62	0.39	-0.25	0.72	1.0	-0.05	0.74	0.61	0.76	0.8	0.25	-0.1	0.5		0.66	0.23
Other Liab	-0.01	0.81	0.9	0.8	-0.58	-0.22	0.73	-0.5	0.51	-0.02	0.57	0.63	-0.24	0.91	0.65	-0.62	0.96	0.43	0.34	0.93	0.11	-0.06	0.41	0.66		0.04
Current Deferred Revenue	-0.11	0.17	0.19	0.49	-0.25	0.58	0.19	-0.26	0.32	0.02	0.54	-0.27	-0.23	0.14	0.23	0.24	0.15	0.36	0.19	0.28	0.58	-0.17	-0.02	0.23	0.04

Click cells to compare fundamentals

Rigel Pharmaceuticals Account Relationship Matchups

Rigel Pharmaceuticals fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	110.4M	167.3M	134.3M	117.2M	134.8M	142.9M
Short Long Term Debt Total	39.1M	30.6M	41.6M	60.6M	69.7M	73.1M
Other Current Liab	16.9M	37.4M	39.1M	36.2M	41.6M	43.7M
Total Current Liabilities	40.8M	63.6M	65.2M	53.3M	61.3M	64.3M
Total Stockholder Equity	34.0M	30.4M	(13.6M)	(28.6M)	(25.8M)	(24.5M)
Property Plant And Equipment Net	20.6M	11.9M	2.8M	1.0M	1.2M	1.1M
Net Debt	8.7M	11.7M	17.1M	27.8M	32.0M	33.6M
Retained Earnings	(1.3B)	(1.3B)	(1.4B)	(1.4B)	(1.3B)	(1.2B)
Accounts Payable	3.7M	3.8M	22.5M	7.1M	8.2M	4.3M
Cash	30.4M	18.9M	24.5M	32.8M	37.7M	32.8M
Non Current Assets Total	21.4M	12.9M	18.4M	18.0M	20.7M	21.7M
Non Currrent Assets Other	824K	974K	640K	3.1M	2.7M	2.9M
Cash And Short Term Investments	57.3M	125.0M	58.2M	56.9M	65.5M	122.1M
Net Receivables	16.0M	15.5M	40.3M	30.6M	35.1M	36.9M
Common Stock Total Equity	168K	169K	172K	174K	200.1K	210.1K
Common Stock Shares Outstanding	16.9M	17.0M	17.2M	17.4M	20.0M	19.0M
Liabilities And Stockholders Equity	110.4M	167.3M	134.3M	117.2M	134.8M	142.9M
Non Current Liabilities Total	35.5M	73.4M	82.7M	92.6M	106.5M	111.8M
Other Current Assets	14.0M	14.8M	8.3M	6.3M	7.2M	4.3M
Other Stockholder Equity	1.3B	1.4B	1.4B	1.4B	1.6B	868.0M
Total Liab	76.4M	137.0M	147.9M	145.9M	167.7M	176.1M
Property Plant And Equipment Gross	20.6M	26.4M	13.6M	2.7M	3.1M	3.0M
Total Current Assets	89.0M	154.5M	115.9M	99.3M	114.2M	133.6M
Accumulated Other Comprehensive Income	(4K)	(102K)	(153K)	8K	9.2K	9.7K
Short Term Debt	17.2M	19.8M	2.3M	8.6M	9.9M	10.4M
Common Stock	169K	172K	174K	175K	201.3K	211.3K
Other Liab	1.5M	6.5M	5.0M	52.7M	60.6M	63.7M
Current Deferred Revenue	3.0M	2.6M	13.5M	1.4M	1.6M	1.5M
Other Assets	696K	824K	974K	640K	576K	547.2K
Long Term Debt	19.8M	19.9M	39.4M	52.4M	60.2M	63.2M
Short Term Investments	27.0M	106.1M	33.7M	24.1M	27.8M	26.4M
Property Plant Equipment	2.2M	2.7M	11.9M	857K	771.3K	732.7K
Net Tangible Assets	74.4M	44.7M	30.4M	(28.6M)	(25.7M)	(24.4M)
Retained Earnings Total Equity	(1.3B)	(1.3B)	(1.3B)	(1.4B)	(1.2B)	(1.3B)
Capital Surpluse	1.3B	1.3B	1.4B	1.4B	1.6B	1.3B
Inventory	1.6M	6.6M	9.1M	5.5M	6.4M	6.7M
Non Current Liabilities Other	5.0M	52.7M	43.2M	39.9M	45.9M	48.2M
Net Invested Capital	53.8M	50.3M	25.8M	31.0M	27.9M	49.7M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Rigel Pharmaceuticals is a strong investment it is important to analyze Rigel Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Rigel Pharmaceuticals' future performance. For an informed investment choice regarding Rigel Stock, refer to the following important reports:

How To Invest In Rigel

Details

Is Rigel Stock a good investment?

Details

What is Rigel Pharmaceuticals' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Rigel Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

For more information on how to buy Rigel Stock please use our How to buy in Rigel Stock guide.

You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Rigel Pharmaceuticals. If investors know Rigel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Rigel Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.48)

Earnings Share

0.27

Revenue Per Share

8.979

Quarterly Revenue Growth

0.966

Return On Assets

0.0461

The market value of Rigel Pharmaceuticals is measured differently than its book value, which is the value of Rigel that is recorded on the company's balance sheet. Investors also form their own opinion of Rigel Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Rigel Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Rigel Pharmaceuticals' market value can be influenced by many factors that don't directly affect Rigel Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Rigel Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Rigel Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Rigel Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Rigel Long Term Debt vs Deferred Long Term Liab Analysis

Long Term Debt vs Deferred Long Term Liab

Long Term Debt vs Deferred Long Term Liab Correlation Analysis

Correlation Coefficient

Long Term Debt

Deferred Long Term Liab

Rigel Pharmaceuticals fundamental ratios Correlations

Rigel Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Rigel Pharmaceuticals fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Common Stock	+ 1.0	Common Stock Total Equity
Total Current Assets	+ 0.99	Total Assets
Total Liab	+ 0.98	Non Current Liabilities Total
Total Current Assets	+ 0.97	Cash And Short Term Investments
Other Liab	+ 0.96	Non Current Liabilities Total
Total Liab	+ 0.95	Other Current Liab

Common Stock	- 0.91	Retained Earnings
Other Stockholder Equity	- 0.91	Retained Earnings
Common Stock Total Equity	- 0.91	Retained Earnings
Total Stockholder Equity	- 0.77	Other Current Liab
Retained Earnings	- 0.74	Total Current Liabilities
Total Stockholder Equity	- 0.73	Total Current Liabilities